Email this article 
Post a Comment SPECIAL APPROACHES TO BREAST CANCER HORMONAL THERAPY OF YOUNG PATIENTS
- Authors: Kravchenko DN1, Parokonnaya AA1, Nechushkin MI1, Avtomonov DE1
-
Affiliations:
- ФГБУ «Российский Онкологический Научный Центр им. Н.Н. Блохина» Минздрава России
- Issue: Vol 7, No 2 (2016)
- Pages: 15-20
- Section: Articles
- URL: https://journals.rcsi.science/clinpractice/article/view/8093
- DOI: https://doi.org/10.17816/clinpract7215-20
- ID: 8093
Cite item
Full Text
Abstract
Breast cancer is the most prevalent female malignancy. When diagnosed at young age (up to 40 years), negative clinical, morphological and prognostic features are noted. A non-randomized retrospective trial (n=500) was performed to evaluate different scenarios of breast cancer hormone therapy in young patients. Ovarian suppression in young patients is shown to statistically improve prognosis. Disease-free survival rate values are observed to decrease in patients without ovarian suppression in comparison with any type of ovarian suppression, especially at a remote follow-up (after 60 months). Menstrual function resumption and no amenorrhea after chemotherapy significantly decrease disease-free survival rate values in young patients.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
D N Kravchenko
ФГБУ «Российский Онкологический Научный Центр им. Н.Н. Блохина» Минздрава России
Email: juramento@yandex.ru
A A Parokonnaya
ФГБУ «Российский Онкологический Научный Центр им. Н.Н. Блохина» Минздрава России
Email: ANAPAR1@yandex.ru
врач онколог-маммолог, д.м.н.
M I Nechushkin
ФГБУ «Российский Онкологический Научный Центр им. Н.Н. Блохина» Минздрава Россиируководитель отделения радиохирургии, д.м.н., профессор
D E Avtomonov
ФГБУ «Российский Онкологический Научный Центр им. Н.Н. Блохина» Минздрава России
Email: dgino@yandex.ru
врач-онколог, к.м.н.
References
- DeSantis C, Siegel R, Bandi P, et al. Breast cancer statistics, 2011. CA Cancer J Clin 2011;61:409-18.
- Francis P. Optimal adjuvant therapy for very young breast cancer patients. Breast. 2011 Aug; 20(4): 297-302.
- Torino F., Barnabei A., de Vecchis L., et al. Chemotherapy-induced ovarian toxicity in patients affected by endocrine-responsive early breast cancer Crit Rev Oncol Hematol. 2014 Jan;89(1):27-42.
- Taylor C.W., Green S., Dalton W.S. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive breast cancer: an intergroup study. J Clin Oncol. 1998 Mar;16(3):994-9.
- Puhalla S, Bhattacharya S, Davidson NE. Hormonal therapy in breast cancer: a model disease for the personalization of cancer care. Mol Oncol. 2012 Apr; 6(2):222-36.
- Wu S, Li Q, Zhu Y, Sun J, Li F, et al. Role of goserelin in combination with endocrine therapy for the treatment of advanced breast cancer in premenopausal women positive for hormone receptor: a retrospective matched case-control study. Cancer biotherapy and pharmaceuticals. Cancer Biother Radiopharm. 2013 Dec; 28 (10): 697-702.
- Ignatiadis M, Buyse M, Sotiriou C. St Gallen International Expert Consensus on the primary therapy of early breast cancer: an invaluable tool for physicians and scientists. Ann Oncol. 2015 Aug; 26 (8):1519-20.
- Moore H., Unger J., Kelly A., et al. Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy NEJM 2015; 372(10): 923-32.
- Lambertini M, Ceppi M, Poggio F, et al. Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. Ann Oncol. 2015 Dec; 26 (12): 2408-19.
